According to the IMS, Afrezza total scripts were down 0.3% wk/wk.
For comparison, here are the Rx metrics for relevant competitors: Humalog total scripts were down 1.6% wk/wk. Novolog total scripts were down 2.2% wk/wk. Apidra total scripts were up 1.2% wk/wk.
Like most statistics, it's what you use the numbers for that matters. Data is valuable. You just have to know how to use it.
One can make the assumption that since a 35% profit share roughly equates to a miud-20s royalty, that costs are estimates to be about 25% so SNY would get ~ 50% of revenue as profit or 1.5B vs. MNKD 1B for the 3B sales. Of course, SNY still needs to pay the sales force from the gross profit.
People readily choose to smoke for non-life preserving reasons. Choosing to inhale somehting that has life preserving qualities for a specific individual probably isn't a great barrier.
No offense but if you want to talk the talk, walk the walk. Write one or more articles published on SA, don't complain about the guy who did.
PLEASE keep the political discussions off the board. It will only go down hill.
That being said, please consider the following: If it gets down to an election between Jeb and Hillary, either way there will be a bush in the White House.
Not sure I buy it. If it was difficult to reproduce, it would be difficult to be repeatable batch to batch from the existing line. That coupled with my uninformed opinion that a major setback would be material and need to be reported, Considering that current demand is well below the capacity of the existing line I'm of the opinion that the lack of a push is for some other strategic reason on the SNY/MNKD plan. I'd offer that they are waiting to announce the new production capacity at a future designed event. You guess is as good as mine what that event will be.